Know Cancer

or
forgot password

Eligibility Screening of Patients With CNS Tumors for NCI Clinical Research Protocols


N/A
18 Years
N/A
Open (Enrolling)
Both
Central Nervous System Neoplasms

Thank you

Trial Information

Eligibility Screening of Patients With CNS Tumors for NCI Clinical Research Protocols


BACKGROUND:

-Adult patients (greater than or equal to 18 yrs of age) with tumors of the central nervous
system who are being evaluated by the Neuro-Oncology Branch (NOB) for National Cancer
Institute (NCI) primary research protocols will be entered onto this screening protocol for
eligibility screening.

OBJECTIVE:

- Evaluate patients with tumors of the Central Nervous System (CNS) for eligibility in
National Cancer Institute (NCI) research protocols.

ELIGIBILITY:

- Patients with tumors of the CNS or a history of a CNS tumor who are being evaluated for
protocols within the National Cancer Institute.

DESIGN:

- The screening tests and procedures that are required by the primary research protocols
will be conducted in order to establish eligibility for these protocols.

- These procedures may include, but are not limited to, laboratory tests on blood, CSF,
urine, or other specimens, and radiographic and nuclear medicine studies, which may
require the administration of contrast or a radioisotopic tracer.

- In some cases, specific research samples required for the primary research protocol may
be collected during the screening process in order to prevent us from having to subject
the patient to a painful procedure on multiple occasions (e.g., bone marrow
aspirations).

- Research specimens will be discarded, if the patient is not eligible for or elects not
to enroll on the primary research protocol. A total of 3000 patients will be enrolled.

Inclusion Criteria


- INCLUSION CRITERIA:

Adult patients (greater than or equal to 18 yrs of age) with tumors of the CNS or a
history of a CNS tumor who are being evaluated for protocols within the National Cancer
Institute.

All patients or their previously designated LAR (Legally Authorized Representative) (if
the patient is deemed by the treating physician to be impaired or questionably impaired in
such a way that the ability of the patient to give informed consent is questionable) must
sign an informed consent indicating that they are aware of the investigational nature of
this study and the risks of the procedures that will be performed to assess eligibility
for primary research protocols.

EXCLUSION CRITERIA:

None

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Teri N Kreisl, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

020186

NCT ID:

NCT00035373

Start Date:

April 2002

Completion Date:

Related Keywords:

  • Central Nervous System Neoplasms
  • Tumor
  • Brain
  • Chemotherapy
  • Anti-Angiogenesis
  • Radiation Therapy
  • CNS Tumor
  • Neoplasms
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892